Squaric Acid Dibutyl Ester

Squaric Acid Dibutyl Ester

SCHEMBL56180

CCCCOc1c(OCCCC)c(=O)c1=O

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.44
THRA P10827 1/20 0.43
THRB P10828 1/20 0.43
CA12 O43570 3/20 0.41
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
CA9 Q16790 3/20 0.41
CA7 P43166 2/20 0.41
TSHR P16473 2/20 0.41
LTA4H P09960 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CA3 P07451 1/20 0.39
CA4 P22748 1/20 0.39
CA6 P23280 1/20 0.39
CA14 Q9ULX7 1/20 0.39
CA5B Q9Y2D0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9809602 0.92 THRA (0.44) CYP3A4THRATHRBTSHRLTA4H
SCHEMBL6658770 0.90 THRA (0.46) THRATHRBTSHRALDH1A1LMNA
SCHEMBL9809623 0.90 THRA (0.46) THRATHRBTSHRALDH1A1LMNA
SCHEMBL9809613 0.90 THRA (0.46) THRATHRBTSHRALDH1A1LMNA
SCHEMBL9809630 0.90 THRA (0.46) THRATHRBTSHRALDH1A1LMNA
SCHEMBL26278000 0.90 THRA (0.46) THRATHRBTSHRALDH1A1LMNA
SCHEMBL26278001 0.90 THRA (0.46) THRATHRBTSHRALDH1A1LMNA
SCHEMBL11629896 0.89 CYP3A4 (0.41) CYP3A4THRATHRBCA12CA1
SCHEMBL7112689 0.86 ALDH1A1 (0.40) CYP3A4THRATHRBCA12CA1
Squaric Acid Dibutyl Ester SCHEMBL2304620 0.85 THRA (0.36) CYP3A4THRATHRBCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 920 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138973-A1 SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE SITRYX THERAPEUTICS LTD (GB) 2026-05-21 US claimed
US-20260137680-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LTD (GB) 2026-05-21 US claimed
US-20260085061-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS SITRYX THERAPEUTICS LIMITED (GB) 2026-03-26 US claimed
EP-3788093-B1 SQUARIC ACID-BASED POLYMERS, THEIR MANUFACTURING PROCESSES AND THEIR USES HYDRO QUEBEC (CA) 2025-12-10 EP claimed
EP-4634167-A1 SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE Sitryx Therapeutics Limited (GB) 2025-10-22 EP claimed
EP-4612132-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS Sitryx Therapeutics Limited (GB) 2025-09-10 EP claimed
US-20250206917-A1 COMPOSITION MERCK PATENT GMBH (DE) 2025-06-26 US claimed
US-20250194617-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2025-06-19 US claimed
CN-120166987-A Phthalazine derivatives as pyruvate kinase modulators 西特瑞治疗有限公司 2025-06-17 CN claimed
US-20250169514-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2025-05-29 US claimed
EP-0743573-B1 Method for obtaining image contrast migration imaging members XEROX CORP (US) 2000-09-06 EP claimed
US-5846559-A Skin patch for use in contact immunotherapy HOPP ROBERT B (US) 1998-12-08 US claimed
EP-0743573-A2 Method for obtaining image contrast migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
EP-0743574-A2 Migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
WO-1996032142-A1 SKIN PATCH FOR USE IN CONTACT IMMUNOTHERAPY HOPP ROBERT B (US) 1996-10-17 WO claimed
US-5563014-A SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT XEROX CORPORATION (US) 1996-10-08 US claimed
US-5514505-A SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE XEROX CORPORATION (US) 1996-05-07 US claimed
US-4585895-A Processes for the preparation of mixed squaraine compositions XEROX CORPORATION (US) 1986-04-29 US claimed
US-4525592-A Process for squaraine compositions XEROX CORPORATION (US) 1985-06-25 US claimed
US-4092146-A POSTEMERGENCE HERBICIDES, PLANT GROWTH INHIBITORS, DESSICANTS, ETHERS OF CYCLOBUTENEDIONE CIBA-GEIGY CORPORATION (US) 1978-05-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260085061-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS PDK1, PDK2, PDK4 CYP3A4 2615/4885THRA 497/4885THRB 142/4885
US-20260137680-A1 NOVEL COMPOUNDS CCR1, CCR4, CCR3 CYP3A4 219/4885THRA 4101/4885THRB 3540/4885
US-20260138973-A1 SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE CCR1, CCR2, CBR1 CYP3A4 1091/4885THRA 2471/4885THRB 2707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.